3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
28
Rectal Neoplasms
25
Stomach Neoplasms
24
Colonic Neoplasms
13
Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma
3
Gastrointestinal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Turcot syndrome
1
Recurrence
1
Rcctal Cancer
1
Peripheral Nervous System Diseases
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Rectal Cancer
1
Locally Advanced Gastric Cancer
1
Locally Advanced Colorectal Cancer
1
Intestinal Neoplasms
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
HER2-positive Colorectal Cancer
1
Gastrointestinal Diseases
1
Gastric Cancer Stage
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Colorectal Cancer Metastatic
1
Colonic Diseases
1
Carcinoma
1
Adenocarcinoma of the Lower Rectum
1
Interventions
Cyclophosphamide
151
Dexamethasone
140
Rituximab
83
fludarabine
78
Cytarabine
69
Lenalidomide
68
Bortezomib
63
fludarabine phosphate
62
Gemcitabine
62
venetoclax
54
Etoposide
53
pembrolizumab
52
pomalidomide
48
Paclitaxel
48
Cisplatin
47
Carboplatin
47
Peripheral Blood Stem Cell Transplantation
46
Filgrastim
40
Radiotherapy
39
Calcium Dobesilate
36
Busulfan
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
29
Vincristine
28
Temozolomide
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Recurrence
×
XELOX
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled